Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.
Significant fluctuations in PET and CT reimbursement rates have made it especially challenging to keep up with this complex topic. We spoke to an expert to learn more.
By binding the substance to a radiotracer, experts were able to improve the accuracy of identifying these tumors by as much as 30% compared to the standard of care.
The newly approved radiotracer is seen as a major step forward for nuclear imaging technology. Specialists have been looking forward to its arrival on the market for quite some time.
The American Society of Nuclear Cardiology recently met with the Louisville, Kentucky, insurer, which shared an openness to reviewing a recent coverage determination.
Multiple nuclear medicine and cardiology groups are working to oppose potential cuts to myocardial PET scans that were made possible by the CMS 2020 Medicare Physician Fee Schedule (MPFS) proposed rule, according to a joint statement.
When CMS released the 2020 Medicare Physician Fee Schedule (MPFS) proposed rule, it included revisions that could lead to technical component payment reductions of up to 80% for certain services related to myocardial PET scans.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the American Society of Nuclear Cardiology (ASNC) submitted a letter to BlueCross BlueShield (BCBS) of Tennessee urging an expansion of cardiac PET coverage.
PET with 11C-PIB provides a noninvasive method for visualizing amyloid deposits in the heart, according to a study published in the February issue of the Journal of Nuclear Medicine. The researchers suggest that 11C-PIB eventually may be used in the clinical setting as both a diagnostic tool and a treatment follow-up method.